Insight

Paolo Tarantino: The TRAIN3 trial of MRI-guided TCHP is out in The Lancet Oncology

Photo generated from www.thelancet.com

Apr 8, 2024, 15:49

Paolo Tarantino: The TRAIN3 trial of MRI-guided TCHP is out in The Lancet Oncology

Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, recently shared on X:

“The TRAIN3 trial of MRI-guided TCHP (3, 6 or 9 cycles) is out in The Lancet Oncology. MRI identified patients with HR-/HER2+ breast cancer having pCR after only 3 cycles of TCHP. May it be MRI, PET, GEP, or ctDNA, the future of treatment for HER2+ eBC will be biomarker driven.”

Read further.
Source: Paolo Tarantino/X

biomarkers Breast Cancer cancer Cancer Diagnosis HR-/HER2+ MRI MRI-guided TCHP OncoDaily Oncology Paolo Tarantino The Lancet The Lancet Oncology TRAIN3 trial

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage